Small molecule · Inhibitor of cyclin-dependent kinase 9 (CDK9) · developed by Prelude Therapeutics
PRT2527 is a selective inhibitor of CDK9, the catalytic subunit of the P-TEFb elongation factor. It binds CDK9 and blocks its kinase activity, preventing phosphorylation of RNA polymerase II and transcription of anti-apoptotic proteins and oncogenic transcription factors such as MYC. It is being studied in B-cell lymphomas, chronic lymphocytic leukemia, T-cell lymphoma, and myeloid malignancies.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05665530 | Phase 1 | Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL) | Completed | PRLD |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Acute Myeloid Leukemia (AML)Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL)Chronic Myelomonocytic Leukemia (CMML)Diffuse Large B-cell Lymphoma (DLBCL)Mantle Cell Lymphoma (MCL)Marginal Zone LymphomaMDS/Myeloproliferative Neoplasm (MPN) Overlap SyndromeMyelodysplastic Syndrome (MDS)Myeloid MalignanciesRichter's SyndromeT-cell Lymphoma
Updated Oct 25, 2026. Something wrong or missing? Report it on the PRLD page.
See PRLD's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
PRLD catalysts and pipeline →